As fears of a potentially devastating Ebola outbreak intensify, researchers are mobilising to develop three new vaccines targeting the Bundibugyo species of the virus. This urgent response comes in light of a situation that has already claimed nearly 250 lives in the Democratic Republic of Congo (DRC), with over 1,000 suspected cases reported. The International Aids Vaccine Initiative (IAVI) has indicated that the current outbreak has the potential to become one of the deadliest in history, echoing the catastrophic epidemic that impacted West Africa from 2014 to 2016.
Rising Concerns Over Ebola’s Spread
The DRC’s Ituri province has emerged as a focal point in the ongoing crisis, where healthcare resources are severely limited due to ongoing conflict. The outbreak has also crossed borders, with nine confirmed cases now identified in Uganda. Dr Mark Feinberg, head of IAVI, expressed grave concerns regarding the outbreak’s severity, stating, “This is clearly threatening to be as severe an outbreak as that, if not even worse.” Such remarks underline the urgency for effective countermeasures, including the timely development of vaccines.
Médecins Sans Frontières (MSF) has described the situation as “deeply alarming,” noting that the rapid increase in cases is unprecedented. The organisation’s remarks highlight the dire need for immediate action to control the spread of the virus, as never before have so many cases been recorded in such a short timeframe.
Vaccine Development Initiatives
Given the unique challenges posed by the Bundibugyo species—one of six known types of Ebola, but only one of three that have caused outbreaks—scientists are racing against time. While a vaccine exists for the Zaire species, Bundibugyo has only been documented in two prior outbreaks, and no approved vaccine is currently available.
IAVI is developing a modified version of the Zaire Ebola vaccine, specifically designed to combat Bundibugyo. Early trials in monkeys have shown promising results, with the vaccine eliciting an immune response that provided close to 100% protection. Dr Feinberg noted that while optimism surrounds the vaccine’s potential, clinical trials could take seven to nine months to initiate—although efforts are underway to accelerate this timeline.
In parallel, Moderna is leveraging its mRNA technology, which was instrumental in the rapid development of COVID-19 vaccines, to create a Bundibugyo vaccine. Stéphane Bancel, the company’s CEO, emphasised their commitment to act swiftly and scientifically to support the response efforts.
Meanwhile, the University of Oxford is also working on a vaccine using its own technology, which had previously saved lives during the COVID-19 pandemic. This vaccine is anticipated to enter clinical trials within two to three months, providing a glimmer of hope in an otherwise grim scenario.
Diverse Approaches to Vaccine Development
Each of the three vaccine candidates employs a unique methodology to prepare the immune system to recognise the Bundibugyo glycoprotein, a key structure on the virus’s surface. IAVI’s approach utilises a harmless, live virus engineered to present the Ebola glycoprotein to the immune system. In contrast, both the mRNA and Oxford vaccines introduce a segment of genetic code that instructs the body to produce the Bundibugyo glycoprotein, prompting an immune response.
Despite these differences, the primary goal remains the same: to enhance the immune system’s readiness in the event of a real Ebola infection. However, variations in technology and immune training methods may influence the effectiveness of each vaccine, necessitating thorough testing during clinical trials.
The Coalition for Epidemic Preparedness Innovations (CEPI) is funding these early research stages, underscoring the critical nature of swift vaccine development. Dr Richard Hatchett, CEO of CEPI, stated, “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.”
The Global Health Perspective
The World Health Organization (WHO) has weighed in on the urgency of developing a Bundibugyo vaccine, which could play a vital role not only in controlling the current epidemic but also in bolstering preparedness for future outbreaks. Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General, highlighted the necessity of such a vaccine in mitigating the impacts of this and future epidemics.
Why it Matters
The rapid development of vaccines against the Bundibugyo strain of Ebola is not merely a scientific endeavour; it is a critical public health imperative. As the world grapples with the potential for another catastrophic outbreak, the advancements in vaccine technology and the collaborative efforts of various organisations could be pivotal in saving thousands of lives. The stakes are high, and the clock is ticking. Immediate action and global cooperation are essential to ensure that history does not repeat itself.
